Phylogica enters into Research and Licensing Agreement with Genentech

23-Dec-2014 - Australia

Phylogica Ltd  announced that it has extended its collaboration with Genentech by entering into a Research and Licensing agreement to discover novel antibiotics. Phylogica  will  employ  its  Phylome® drug  discovery  platform,  including  its  proprietary  cellpenetrating  peptide  discovery  technology  to  identify  Phylomer  peptides  suitable  for  further evaluation. 

Under the terms of the agreement, Phylogica will receive an upfront payment of US$500,000. In addition, Phylogica is eligible to receive research, development, and commercialization milestone payments totaling up to US$142 million.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?